← Back to patent-cliff list
Arsenic Trioxide
Tier C — Watch / tradeArsenic Trioxide
Teva Pharmaceutical Industries
Originator
2000
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TrxR
Brand：Trisenox, Arscimed
Indications (approved)：Liver cancer, Acute promyelocytic leukaemia
Regional status
US
Approved
2000-09-25
EU
Approved
2002-03-05
China
Approved
2008-09-22
Japan
Approved
2004-12-08
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Arsenic Trioxide?
Approved indications include: Liver cancer, Acute promyelocytic leukaemia.
When does the Arsenic Trioxide patent expire?
No public expiry year is available for Arsenic Trioxide yet; this page updates once verified.
How do I get a quote for Arsenic Trioxide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27